# The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy

> **NCT01181765** · PHASE4 · COMPLETED · sponsor: **Janssen Inc.** · enrollment: 1 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** Infliximab 5 mg/kg body weight infused over 2 hours

## Key facts

- **NCT ID:** NCT01181765
- **Lead sponsor:** Janssen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2013-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01181765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01181765, "The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01181765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*